The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. RESULTS: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. CONCLUSIONS: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of CATT participants (>92%) had stable or improved VA relative to baseline.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Comparison of AMD Treatments Trials (CATT) showed that bevacizumab was equivalent to ranibizumab in improving visual acuity (VA) of patients with neovascular AMD when treatment was administered either monthly or pro re nata (PRN).1”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this remarkable clinical effect, there was a wide range in treatment response.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“At one year, participants treated monthly with bevacizumab or ranibizumab gained 8.0 and 8.5 letters, respectively, and those treated as needed gained 5.9 and 6.8 letters, respectively.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Cited by
Sorted by citations
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,545
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,285
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,806
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Papadopoulos, N. J., Martin, J. H., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,060
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,074
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
Mechanisms of Age-Related Macular Degeneration
Ambati, J., & Fowler, B. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.018 · Cited by 1,062
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C. W., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 1,093
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Analysis of aptamer discovery and technology
Dunn, M. R., Jimenez, R. M., & Chaput, J. C. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0076 · Cited by 938
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
Gross, J. G., Glassman, A. R., Jampol, L. M., Inusah, S., Aiello, L. P., Antoszyk, A. N., Baker, C. W., Berger, B. B., Bressler, N. M., Browning, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.15217 · Cited by 801
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 787
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Inflammation and its role in age-related macular degeneration
Kauppinen, A., Paterno, J. J., Błasiak, J., Salminen, A., & Kaarniranta, K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2147-8 · Cited by 683
Schmidt-Erfurth, U. M., Chong, V. N., Loewenstein, A., Larsen, M., Souied, E. H., Schlingemann, R. O., Eldem, B. M., Monés, J., Richard, G. W., & Bandello, F. M. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 678
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Ho, A. C., BUSBEE, B. G., Regillo, C. D., Wieland, M. R., Everen, S. A. V., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 594
Immunology of age-related macular degeneration
Ambati, J., Atkinson, J. P., & Gelfand, B. D. (2013) · Nature reviews. Immunology · doi:10.1038/nri3459 · Cited by 606
Age-Related Macular Degeneration
Fleckenstein, M., Schmitz-Valckenberg, S., & Chakravarthy, U. (2024) · JAMA · doi:10.1001/jama.2023.26074 · Cited by 595
Deep learning in ophthalmology: The technical and clinical considerations
Ting, D. S. W., Peng, L. H., Varadarajan, A. V., Keane, P. A., Burlina, P., Chiang, M. F., Schmetterer, L. F., Pasquale, L. R., Bressler, N. M., Webster, D. R., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.04.003 · Cited by 566
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 571
Prevalence of Age-Related Macular Degeneration in Europe
Colijn, J. M., Buitendijk, G. H. S., Prokofyeva, E., Alves, D., Cachulo, M. L., Khawaja, A. P., Cougnard‐Grégoire, A., Merle, B. M. J., Korb, C. A., Erke, M. G., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.035 · Cited by 524
Rezvan, P. H., Lee, K. J., & Simpson, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0022-1 · Cited by 483
Age-Related Macular Degeneration
Thomas, C. J., Mirza, R. G., & Gill, M. K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.01.003 · Cited by 490
Doyle, S., Campbell, M., Ozaki, E., Salomon, R. G., Mori, A., Kenna, P. F., Farrar, G. J., Kiang, A., Humphries, M. M., Lavelle, E. C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2717 · Cited by 428
Recent developments in age-related macular degeneration: a review
Al-Zamil, W. M., & Yassin, S. A. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143508 · Cited by 427
Animal models of age related macular degeneration
Pennesi, M. E., Neuringer, M., & Courtney, R. J. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.003 · Cited by 391
“As a result, anti-VEGF therapy has dramatically altered the prognosis for patients afflicted with exudative AMD and shifted the therapeutic paradigm to increasingly targeted pharmacotherapy (Martin et al., 2011).”
BackgroundA paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
Berg, K., Pedersen, T. R., Sandvik, L., & Bragadóttir, R. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.041 · Cited by 400
Campochiaro, P. A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0993-5 · Cited by 400
Rajendram, R., Fraser‐Bell, S., Kaines, A., Michaelides, M., HAMILTON, R. D., Esposti, S. D., Pető, T., Egan, C. A., Bunce, C., Leslie, R. D., et al. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.393 · Cited by 387
Avery, R. L., CASTELLARIN, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R. F., Couvillion, S. S., Nasir, M. A., Rabena, M., Le, K. N., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305252 · Cited by 385
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J., Garg, N. K., Lunde, E., Han, K., Jain, S. K., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 396
Farsiu, S., Chiu, S. J., O’Connell, R. V., Folgar, F. A., Yuan, E. L., Izatt, J. A., & Toth, C. A. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.013 · Cited by 370
Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.016 · Cited by 356
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab
Monés, J., Srivastava, S. K., Jaffe, G. J., Tadayoni, R., Albini, T. A., Kaiser, P. K., Holz, F. G., Korobelnik, J.-F., Kim, I. K., Pruente, C., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.11.011 · Cited by 351
Mettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Risk factors and biomarkers of age-related macular degeneration
Lambert, N. G., Elshelmani, H., Singh, M. K., Mansergh, F. C., Wride, M. A., Padilla, M., Keegan, D., Hogg, R. E., & Ambati, B. K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.003 · Cited by 367
Avery, R. L., CASTELLARIN, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R. F., Couvillion, S. S., Nasir, M. A., Rabena, M., Maia, M., et al. (2017) · Retina · doi:10.1097/iae.0000000000001493 · Cited by 360
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A. A., Lim, J. I., Vemulakonda, G. A., & Ying, G. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 367
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 358
Bourne, R., Jonas, J. B., Bron, A. M., Cicinelli, M. V., Das, A., Flaxman, S. R., Friedman, D. S., Keeffe, J. E., Kempen, J. H., Leasher, J. L., et al. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311258 · Cited by 370
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W., Ogura, Y., Yeo, I. Y. S., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 345
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
“Patients were examined approximately every 28 days.(10) Stereoscopic CFP, FA, and OCT scans were obtained at baseline, 1 year, and 2 years.”
Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo
Xu, Q., Boylan, N. J., Suk, J. S., Wang, Y.-Y., Nance, E. A., Yang, J., McDonnell, P. J., Cone, R. A., Duh, E. J., & Hanes, J. S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.018 · Cited by 339
Targeted deletion of Vegfa in adult mice induces vision loss
Kurihara, T., Westenskow, P. D., Bravo, S., Aguilar, E., & Friedlander, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65157 · Cited by 331
Guymer, R. H., Markey, C. M., McAllister, I. L., Gillies, M. C., Hunyor, A. P., Arnold, J. J., Chang, A., Syed, A., Broadhead, G., Pham, T., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.025 · Cited by 317
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 320
Ying, G.-S., Huang, J., Maguire, M. G., Jaffe, G. J., Grunwald, J. E., Toth, C., Daniel, E., Klein, M., Pieramici, D., Wells, J., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.042 · Cited by 305
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Kim, B., Park, J., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201903637 · Cited by 307
Jaffe, G. J., Martin, D. F., Toth, C. A., Daniel, E., Maguire, M. G., Ying, G.-S., Grunwald, J. E., & Huang, J. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.073 · Cited by 294
(2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.031 · Cited by 283
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES
Freund, K. B., Korobelnik, J., Devenyi, R. G., Framme, C., Galic, J., Herbert, E. N., Hoerauf, H., Lanzetta, P., Michels, S., Mitchell, P., et al. (2015) · Retina · doi:10.1097/iae.0000000000000627 · Cited by 285
Evaluation of Age-related Macular Degeneration With Optical Coherence Tomography
Keane, P. A., Patel, P. J., Liakopoulos, S., Heussen, F. M., Sadda, S. R., & Tufail, A. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.006 · Cited by 291
Lee, W. K., Iida, T., Ogura, Y., Chen, S., Wong, T. Y., Mitchell, P., Cheung, C. M. G., Zhang, Z., Leal, S., Ishibashi, T., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1804 · Cited by 280
The Blood-Retina Barrier: Tight Junctions and Barrier Modulation
Campbell, M., & Humphries, P. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-4711-5_3 · Cited by 270
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K. B., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 280
The Diagnosis and Treatment of Age-Related Macular Degeneration
Stahl, A. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0513 · Cited by 296
A review of anti-VEGF agents for proliferative diabetic retinopathy
Osaadon, P., Fagan, X. J., Lifshitz, T., & Levy, J. (2014) · Eye · doi:10.1038/eye.2014.13 · Cited by 272
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration
da Silva, R. M., Berta, A., Larsen, M., Macfadden, W., Feller, C., & Monés, J. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.07.014 · Cited by 267
INTRAVITREAL INJECTION TECHNIQUE AND MONITORING
Avery, R. L., Bakri, S. J., Blumenkranz, M. S., Brucker, A. J., Cunningham, E. T., D’Amico, D. J., Dugel, P. U., Flynn, H. W., Freund, K. B., Haller, J. A., et al. (2014) · Retina · doi:10.1097/iae.0000000000000399 · Cited by 268
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub5 · Cited by 263
Long-term outcomes of treatment of neovascular age-related macular degeneration
Gillies, M. C., Campain, A., Barthelmes, D., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Essex, R. W., Morlet, N., & Hunyor, A. P. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.010 · Cited by 254
Kodjikian, L., Souied, E. H., Mimoun, G., Mauget‐Faÿsse, M., Béhar‐Cohen, F., Decullier, É., Huot, L., & Aulagner, G. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.06.020 · Cited by 265
Stem cells in retinal regeneration: past, present and future
Ramsden, C. M., Powner, M. B., Carr, A. F., Smart, M. J. K., da Cruz, L., & Coffey, P. J. (2013) · Development · doi:10.1242/dev.092270 · Cited by 259
Miller, J. W. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.10.018 · Cited by 254
Jaffe, G. J., Ying, G., Toth, C. A., Daniel, E., Grunwald, J. E., Martin, D. F., & Maguire, M. G. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.08.035 · Cited by 248
Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration
Holz, F. G., Sadda, S. R., Staurenghi, G., Lindner, M., Bird, A. C., Blodi, B. A., Bottoni, F. G., Chakravarthy, U., Chew, E. Y., Csaky, K. G., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.12.002 · Cited by 251
Fileta, J. B., Scott, I. U., & Flynn, H. W. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20140306-08 · Cited by 249
Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Krohne, T. U., Liu, Z., Holz, F. G., & Meyer, C. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.047 · Cited by 246
Sharma, S., Toth, C. A., Daniel, E., Grunwald, J. E., Maguire, M. G., Ying, G.-S., Huang, J., Martin, D. F., & Jaffe, G. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.002 · Cited by 231
Lotery, A. J., Sivaprasad, S., O’Connell, A., Harris, R. A., Culliford, L. A., Ellis, L. A., Cree, A. J., Madhusudhan, S., Béhar‐Cohen, F., Chakravarthy, U., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32981-2 · Cited by 225
A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis
Kim, L. A., & D'Amore, P. A. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.006 · Cited by 230
Willoughby, A. S., Ying, G., Toth, C. A., Maguire, M. G., Burns, R. E., Grunwald, J. E., Daniel, E., Jaffe, G. J., Williams, D. F., Beardsley, S., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.042 · Cited by 224
Anti-VEGF Treatment Strategies for Wet AMD
Kovach, J. L., Schwartz, S. G., Flynn, H. W., & Scott, I. U. (2012) · Journal of Ophthalmology · doi:10.1155/2012/786870 · Cited by 229
Whitmore, S. S., Sohn, E. H., Chirco, K. R., Drack, A. V., Stone, E. M., Tucker, B. A., & Mullins, R. F. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.11.005 · Cited by 223
Scott, I. U., VanVeldhuisen, P., Ip, M. S., Blodi, B. A., Oden, N. L., Awh, C. C., Kunimoto, D. Y., Marcus, D. M., Wroblewski, J. J., King, J. S., et al. (2017) · JAMA · doi:10.1001/jama.2017.4568 · Cited by 215
Grunwald, J. E., Pistilli, M., Daniel, E., Ying, G.-S., Pan, W., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., Maguire, M. G., & Martin, D. F. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.012 · Cited by 214
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Ricci, F., Bandello, F. M., Navarra, P., Staurenghi, G., Stumpp, M. T., & Zarbin, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218242 · Cited by 224
Stem cell based therapies for age-related macular degeneration: The promises and the challenges
Nazari, H. K., Zhang, L., Zhu, D., Chader, G. J., Falabella, P., Stefanini, F. R., Rowland, T. J., Clegg, D., Kashani, A. H., Hinton, D. R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.004 · Cited by 212
The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology
Stewart, M. W. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.10.001 · Cited by 206
Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Grunwald, J. E., Pistilli, M., Ying, G., Maguire, M. G., Daniel, E., & Martín, D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.007 · Cited by 207
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
Ciulla, T. A., Hussain, R. M., Pollack, J. S., & Williams, D. F. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.017 · Cited by 205
Xu, L., Lu, T., Tuomi, L., Jumbe, N. L. ‘., Lü, J., Eppler, S., Kuebler, P., Damico‐Beyer, L. A., & Joshi, A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10260 · Cited by 208
Schmidt-Erfurth, U. M., Bogunović, H., Sadeghipour, A., Schlegl, T., Langs, G., Gerendas, B. S., Osborne, A. R., & Waldstein, S. M. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.015 · Cited by 201
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Jung, J. J., Chen, C. Y., Mrejen, S., Gallego‐Pinazo, R., Xu, L., Marsiglia, M., Boddu, S., & Freund, K. B. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.006 · Cited by 195
Anti-vascular endothelial growth factor therapy for diabetic macular edema
Boyer, D. S., Hopkins, J. J., Sorof, J. M., & Ehrlich, J. S. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813512360 · Cited by 200
Kauper, K., McGovern, C., Sherman, S., Heatherton, P., Rapoza, R., Stabila, P. F., Dean, B., Lee, A., Borges, S., Bouchard, B., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9970 · Cited by 203
Chew, E. Y., Clemons, T. E., Bressler, S. B., Elman, M. J., Danis, R. P., Domalpally, A., Heier, J. S., Kim, J. E., & Garfinkel, R. A. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.027 · Cited by 196
Metadata
- Authors
- The CATT Research Group
- Corresponding author
- The CATT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-19
- Volume
- 364
- Issue
- 20
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3157322
- OpenAlex
- W1481978003
- Cited by
- 2,669
- References
- 21
- Citations by year
- 2026: 78 · 2025: 91 · 2024: 116 · 2023: 111 · 2022: 127 · 2021: 164 · 2020: 195 · 2019: 151 · 2018: 168 · 2017: 177 · 2016: 199 · 2015: 238 · 2014: 264 · 2013: 248 · 2012: 265
- FWCI
- 254.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, intravitreal injection, anti-VEGF therapy, visual acuity, central retinal thickness, treatment schedule, non-inferiority, serious adverse events, off-label drug use, anti-angiogenic therapy, comparative efficacy and safety, hospitalization
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cardiovascular Diseases, Drug Administration Schedule, Female, Humans, Macular Degeneration, Male, Middle Aged, Retina, Therapeutic Equivalency, Visual Acuity, Proportional Hazards Models, Single-Blind Method, Off-Label Use, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
